CD274 and carcinoma: The administration of immunotherapy in the three patients with PD-L1 tumor proportion scores of 15, 30, and 60%, all achieving stable disease, indicates that checkpoint immunotherapy can be beneficial to pulmonary lymphoepithelioma-like carcinoma patients and can be a treatment option for this subset of patients.